Propel Bio Management, LLC 13F holdings, Q1 2025
Holdings as of March 31, 2025 · filings on SEC EDGAR · latest filing →
Propel Bio Management, LLC disclosed 18 US equity positions worth $86.1m in its Q1 2025 13F filing. The largest position was PAGPEUR at 31.6% of the reported book, followed by MDGL and AKERO THERAPEUTICS INC. Against the Q4 2024 filing, it opened 2 new positions, added to 4 and reduced 2 among the top 18 holdings.
What did Propel Bio Management, LLC own in Q1 2025? Top 18 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q4 2024 |
|---|---|---|---|---|---|---|---|
| 1 | PAGPEUR PLAINS GP HOLDINGS LP-CL | 31.6% | $27.2m | 1,272,360 | 0% | held | |
| 2 | MDGL MADRIGAL PHARMACEUTICALS | Healthcare | 11.6% | $9.9m | 30,032 | -30% | reduced |
| 3 | AKERO THERAPEUTICS INC | 10.8% | $9.3m | 228,884 | -33% | reduced | |
| 4 | PHAT PHATHOM PHARMACEUTICALS I | 8.3% | $7.1m | 1,134,927 | 15% | added | |
| 5 | ACHV ACHIEVE LIFE SCIENCES INC | 7.6% | $6.5m | 2,453,092 | 0% | held | |
| 6 | APLT APPLIED THERAPEUTICS INC | 6.4% | $5.5m | 11,285,420 | 17% | added | |
| 7 | RNAGBP AVIDITY BIOSCIENCES INC | 6.1% | $5.3m | 178,500 | 0% | held | |
| 8 | ABEO ABEONA THERAPEUTICS INC | Healthcare | 3.5% | $3.0m | 624,022 | 0% | held |
| 9 | TCRX TSCAN THERAPEUTICS INC | 3.3% | $2.9m | 2,087,139 | 0% | held | |
| 10 | DCTH DELCATH SYSTEMS INC | 2.6% | $2.3m | 177,600 | 945% | added | |
| 11 | SNDX SYNDAX PHARMACEUTICALS IN | Healthcare | 2.6% | $2.3m | 183,259 | 0% | held |
| 12 | ZVRA ZEVRA THERAPEUTICS INC | 1.6% | $1.3m | 179,874 | 0% | held | |
| 13 | MIST MILESTONE PHARMACEUTICALS | 1.3% | $1.2m | 1,451,557 | – | new | |
| 14 | MAAT PHARMA SACA | 1.2% | $1.0m | 166,423 | 5182% | added | |
| 15 | CMPX COMPASS THERAPEUTICS INC | 0.5% | $433.8k | 228,317 | – | new | |
| 16 | ATHIRA PHARMA INC | 0.5% | $425.3k | 1,492,792 | 0% | held | |
| 17 | 72C EIGER BIOPHARMACEUTICALS | 0.5% | $423.0k | 146,381 | 0% | held | |
| 18 | CHINOOK THERAPEUTICS | 0.0% | $38.5k | 79,357 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.